3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
3
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
3
Carcinoma, Hepatocellular
3
Thyroid Nodule
2
Lung Neoplasms
2
Liver Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Osteosarcoma
1
Leiomyoma
1
Hyperthyroidism
1
Fibrosis
1
Esophageal Squamous Cell Neoplasia (ESCN)
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Barrett Esophagus
1
Interventions
Dexamethasone
29
Cyclophosphamide
21
Rituximab
17
Cytarabine
16
Bortezomib
13
Gemcitabine
12
fludarabine
11
Methotrexate
11
Lenalidomide
10
Filgrastim
10
Vincristine
9
Etoposide
9
pomalidomide
8
pembrolizumab
8
Paclitaxel
8
Azacitidine
8
venetoclax
7
carfilzomib
7
Doxorubicin
7
Docetaxel
7
Cyclosporine
7
Calcium Dobesilate
7
Antilymphocyte Serum
7
fludarabine phosphate
6
Topotecan
6
Temozolomide
6
Radiotherapy
6
Peripheral Blood Stem Cell Transplantation
6
Mitoxantrone
6
daratumumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Recurrence
×
Radiofrequency Ablation
×
Clear all
NCT01486134
2020-05-13
ARMTICH
Assistance Publique - Hôpitaux de Paris
Phase NA
Terminated
15 enrolled